6 hours Drug giant Pfizer sells $3.3 billion stake in Sensodyne-maker Haleon Investing.com Drug giant Pfizer sells $3.3 billion stake in Sensodyne-maker Haleon. Pfizer (PFE)
4 hours Northwestern Mutual Wealth Management Co. Sells 39,053 Shares of Pfizer Inc. (NYSE:PFE)MarketBeat
17 hours Pfizer to sell about $3.25 billion stake in Sensodyne-maker Haleon, bookrunner saysInvesting.com
1 day Pfizer Inc. (PFE) Acquires Seagen for $43 Billion, Strengthening Oncology LeadershipInsider Monkey
5 days Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.Investor's Business Daily
1 week Pfizer Inc. (NYSE:PFE) to Post Q3 2025 Earnings of $0.72 Per Share, Zacks Research ForecastsMarketBeat
1 week Pfizer Inc. (PFE): Strong Q2 2024 Dividend Focus with $5 Billion Returned to ShareholdersInsider Monkey
2 weeks 3 Magnificent Dividend Stocks With Yields Above 5% to Buy Now and Hold ForeverThe Motley Fool
2 weeks Pfizer says drug for deadly cancer condition that causes weight loss shows positive trial dataCNBC
3 weeks The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart MonopolyThe Wall Street Journal
4 weeks Pfizer Inc. (PFE) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)Seeking Alpha
4 weeks Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive MarketInvestor's Business Daily
1 month Pfizer. Inc. (PFE): One of the Best Affordable Stocks Under $40 According to Short SellersInsider Monkey
1 month Why IBD 50’s Alnylam Just Reversed Its 50% Gain — And BridgeBio SurgedInvestor's Business Daily
1 month Want $2,000 in Annual Dividends? Invest $30,000 in These 3 High-Yielding StocksThe Motley Fool
1 month FDA approves new updated COVID-19 vaccines to target KP.2 variant. Here’s what to knowFast Company
2 months Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its MarkInvestor's Business Daily
2 months Pfizer-BioNTech’s COVID-19-and-flu combination drug meets 1 of 2 trial objectivesMarketWatch
2 months Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It’s Not Pfizer)The Motley Fool
2 months Pfizer reports positive results in study of vaccine for immunocompromised adults at risk of severe RSV-related illnessMarketWatch
2 months Pfizer Inc. (PFE): Should You Add This GLP-1 and Weight Loss Stock to Your Portfolio Now?Insider Monkey
2 months Pfizer to Buy a GLP-1 Drugmaker? Here’s Why You Shouldn’t Count on That HappeningThe Motley Fool
2 months Pfizer’s weight loss pill may enter regulatory studies next year, says CEO Albert BourlaYouTube
2 months Drugmaker Pfizer hikes 2024 forecast again after initially underwhelming Wall StreetYahoo Finance